Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Luo, Li ^a   Luo, Bing ^b   Zheng, Ying ^a   Zhang, Heng ^a   Li, Jing ^c   Sidell, Neil ^d  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU WOMEN S AND CHILDREN S CENTRAL HOSPITAL   (China)

^c SICHUAN UNIVERSITY   (China)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYL 6 DEHYDROPROGESTERONE ACETATE; GESTAGEN; HYDROXYPROGESTERONE CAPROATE; LEVONORGESTREL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; SEX HORMONE; UNCLASSIFIED DRUG;

ACNE; BODY WEIGHT GAIN; BREAST TENDERNESS; CLINICAL OUTCOME; DEPRESSION; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; EVIDENCE BASED MEDICINE; HEADACHE; HISTOPATHOLOGY; HUMAN; NAUSEA; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UTERUS BIOPSY; VOMITING; ENDOMETRIAL HYPERPLASIA; FEMALE; INTRAUTERINE CONTRACEPTIVE DEVICE;

ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL;

EID: 84881383399     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009458.pub2     Document Type: Review

References (20)

1. Buttini MJ, Jordan SJ, et al. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. The Australian & New Zealand Journal of Obstetrics & Gynaecology 2009;49(3):316-22.
2. Vilos GA, Marks J, Tureanu V, Abu-Rafea B, Vilos AG. The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. Journal of Minimally Invasive Gynecology 2011;18(1):75-80.
3. Lee SY, Kim MK, Park H, Yoon BS, Seong SJ, Kang JH, et al.The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. Journal of Gynecologic Oncology 2010;21(2):102-5.
4. Chi IC, Farr G. The non-contraceptive of the levonorgestrel-releasing intrauterine device. Advances in Contraception 1994;10(4):271-85.
5. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007245.pub2]
6. Guttinger A, Critchley HO. Endometrial effects of intrauterine levonorgestrel. Contraception 2007;75(6 Suppl):93-8.
7. Guo LN. Atypical hyperplasia and complex hyperplasia of endometrium in women of reproductive age. Zhonghua Fu Chan Ke Za Zhi 1993;28(12):725-7, 760.
8. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
9. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
10. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from www.cochrane-handbook.org.: The Cochrane Collaboration, 2011.
11. Kullander S. Treatment of endometrial cancer with GnRH analogs. Recent Results in Cancer Research 1992;124:69-73.
12. Kurman RJ, Kaminski PF, et al. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56(2):403-12.
13. Luukkainen T. Levonorgestrel-releasing intrauterine device. Annals of the New York Academy of Sciences 1991;626:43-9.
14. Qi X, Zhao W, et al. Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia. Gynecologic and Obstetric Investigation 2008;65(4):266-8.
15. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstetrics and Gynecology 1997;90(3):434-40.
16. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004;47(4):277-83.
17. Sturridge F, Guillebaud J. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Safety 1996;15(6):430-40.
18. Wildemeersch D, Dhont M. Treatment of non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. American Journal of Obstetrics and Gynecology 2003;188(5):1297-8.
19. Wildemeersch D, Janssens D, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007;57(2):210-3.
20. Zhou LY, et al.Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990;41(4):353-62.